31 Participants Needed

GT103 for Non-Small Cell Lung Cancer

Recruiting at 2 trial locations
TS
CA
DM
Overseen ByDCI Multi-Site Studies
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Edward Patz
Must be taking: Immunotherapy, Platinum chemotherapy
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this research study is to determine the maximum tolerated dose of GT103 and investigate the safety and effectiveness of the study drug.

Who Is on the Research Team?

JC

Jeffrey Clarke, MD

Principal Investigator

Duke University

Are You a Good Fit for This Trial?

Adults over 18 with advanced stage III, IV or recurrent NSCLC that's worsened after prior therapy can join. They must have measurable disease, acceptable organ function, and no severe allergies to PD-1/PD-L1 drugs. Participants need a stable ECOG status (0 or 1), adequate bone marrow function, and must use effective contraception.

Inclusion Criteria

My advanced lung cancer has worsened after previous treatment.
Signed informed consent
My liver is functioning within the required limits.
See 9 more

Exclusion Criteria

I haven't had major surgery or significant injury in the last 4 weeks and don't expect to need major surgery during the study.
I need medication for brain-related cancer symptoms.
I am not pregnant, breastfeeding, and if capable of having children, I am using effective birth control.
See 14 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation Treatment

Participants receive GT103 every 3 weeks with dose escalation from 0.3 mg/kg to 10 mg/kg or until the maximum tolerated dose (MTD) is found

2 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 years

What Are the Treatments Tested in This Trial?

Interventions

  • GT103
Trial Overview The trial is testing GT103's highest dose patients can tolerate while checking its safety and effectiveness against advanced non-small cell lung cancer. It involves people whose cancer has progressed despite previous treatments.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: GT103Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Edward Patz

Lead Sponsor

Trials
1
Recruited
30+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security